A242 Vorinostat and Bortezomib in Relapsed/Refractory MM

reported by 2 patients (22%), but were not considered drug-related. No DLT has been observed to date. Of 8 patients evaluable for efficacy, the best responses were: complete response (n = 1), partial response (n = 1), minimal response (n = 2), stable disease (n = 2), and progressive disease (n = 2). Conclusion: These preliminary data suggest that vorinostat plus lenalidomide and dexamethasone represents a novel oral combination therapy that is active and relatively well tolerated in the treatment of relapsed or refractory multiple myeloma. Enrollment is ongoing and study updates will be presented.